Cocrystal pharma highlights its novel inhaled and oral influenza a antiviral cc-42344 at the world vaccine congress west coast

Bothell, wash., nov. 29, 2023 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum pb2 inhibitor cc-42344 against pandemic and seasonal influenza a strains at the world vaccine congress west coast. cocrystal has initiated a phase 2a human challenge trial with oral cc-42344 in the uk in subjects infected with influenza a, and plans to begin a phase 1 trial with inhaled cc-42344 as a potential influenza a treatment and prophylaxis in australia in the first half of 2024.
COCP Ratings Summary
COCP Quant Ranking